Cas:1446690-23-8 4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide manufacturer & supplier

Chemical Name:4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide

CAS.NO:1446690-23-8

Synonyms:4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide

Molecular Formula:N/A

Molecular Weight:N/A

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide Use and application,4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide technical grade,usp/ep/jp grade.

Related News: In order to find answers to these questions, our staff in the development department set about conducting a series of experiments. 4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide manufacturer The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. 4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide supplier The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter. 4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 4-{4-[4-(2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-1-oxy-pyrimidin-2-ylamino}-benzamide factory In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.